NeuroKaire Enters into R&D Collaboration with Compass Pathways to Pioneer Precision Treatments for Depression
NeuroKaire and Compass Pathways (CMPS) announced an R&D collaboration on Oct 30, 2025 to apply NeuroKaire's AI-powered neural image analysis to study how psychedelic compounds affect neuron structure and connectivity.
The study will use stem cell–derived neurons from people with treatment-resistant depression (TRD) and major depressive disorder (MDD), leveraging a proprietary neuroplasticity marker to compare cellular effects across compounds and link findings to clinical phenotypes.
The collaboration aims to narrow the gap between preclinical models and patient outcomes and to inform precision approaches to psychedelic drug development.
NeuroKaire e Compass Pathways (CMPS) hanno annunciato una collaborazione R&D il 30 ottobre 2025 per applicare l'analisi delle immagini neurali basata sull'IA di NeuroKaire per studiare come i composti psichedelici influenzano la struttura neuronale e la connettività.
Lo studio utilizzerà neuroni derivati da cellule staminali provenienti da persone con depressione resistente al trattamento (TRD) e disturbo depressivo maggiore (MDD), sfruttando un marker proprietario di neuroplasticità per confrontare gli effetti cellulari tra i composti e collegare i risultati ai fenotipi clinici.
La collaborazione mira a ridurre il divario tra modelli preclinici e esiti nei pazienti e a informare approcci di precisione nello sviluppo di farmaci psichedelici.
NeuroKaire y Compass Pathways (CMPS) anunciaron una colaboración de I+D el 30 de octubre de 2025 para aplicar el análisis de imágenes neuronales impulsado por IA de NeuroKaire para estudiar cómo los compuestos psicodélicos afectan la estructura y la conectividad de las neuronas.
El estudio utilizará neuronas derivadas de células madre de personas con depresión resistente al tratamiento (TRD) y trastorno depresivo mayor (MDD), aprovechando un marcador de neuroplasticidad propietario para comparar efectos celulares entre compuestos y vincular los hallazgos con fenotipos clínicos.
La colaboración tiene como objetivo acortar la brecha entre modelos preclínicos y resultados en pacientes y orientar enfoques de precisión para el desarrollo de fármacos psicodélicos.
뉴로케어와 Compass Pathways (CMPS)는 2025년 10월 30일에 NeuroKaire의 AI 기반 신경 영상 분석을 적용하여 환각제 성분이 신경 세포의 구조와 연결성에 미치는 영향을 연구하기 위한 연구개발(R&D) 협력을 발표했습니다.
본 연구는 치료에 반응하지 않는 우울증(TRD) 및 주요 우울 장애(MDD)를 가진 사람들의 줄기세포 유래 뉴런을 사용하고, 독점적인 신경가소성 마커를 활용하여 화합물 간 세포 효과를 비교하고 임상 표현형과의 연관성을 도출합니다.
협력의 목표는 전임상 모델과 환자 결과 간의 격차를 좁히고 환각제 약물 개발에 대한 정밀 의학적 접근을 안내하는 것입니다.
NeuroKaire et Compass Pathways (CMPS) ont annoncé une collaboration R&D le 30 octobre 2025 afin d'appliquer l'analyse d'images neuronales alimentée par l'IA de NeuroKaire pour étudier comment les composés psychédéliques affectent la structure et la connectivité des neurones.
L'étude utilisera des neurones dérivés de cellules souches provenant de personnes atteintes de dépression résistante au traitement (TRD) et de trouble dépressif majeur (MDD), tirant parti d'un marqueur de neuroplasticité propriétaire pour comparer les effets cellulaires entre les composés et relier les résultats aux phénotypes cliniques.
La collaboration vise à réduire l'écart entre les modèles précliniques et les résultats chez les patients et à éclairer des approches de précision dans le développement de médicaments psychédéliques.
NeuroKaire und Compass Pathways (CMPS) haben am 30. Oktober 2025 bekannt gegeben, eine F&E-Zusammenarbeit zu starten, um die KI-gestützte neuronale Bildanalyse von NeuroKaire anzuwenden, um zu untersuchen, wie psychedelische Verbindungen die Struktur und Konnektivität von Neuronen beeinflussen.
Die Studie werde neuronale Zellen verwenden, die aus Stammzellen von Personen mit behandelungsresistenter Depression (TRD) und majorer depressiver Störung (MDD) stammen, wobei ein firmeneigener Neuroplastizitätsmarker genutzt werde, um zelluläre Effekte zwischen Verbindungen zu vergleichen und die Befunde mit klinischen Phänotypen zu verknüpfen.
Die Zusammenarbeit ziele darauf ab, die Lücke zwischen präklinischen Modellen und Patientenergebnissen zu verringern und präzisionsorientierte Ansätze in der Entwicklung von Psychedelika zu informieren.
NeuroKaire و Compass Pathways (CMPS) أعلنتا عن تعاون بحثي وتطويري في 30 أكتوبر 2025 لتطبيق تحليل الصور العصبية المدعوم بالذكاء الاصطناعي من NeuroKaire لدراسة كيف تؤثر المركبات المهلوسة على بنية واتصال الخلايا العصبية.
ستستخدم الدراسة خلايا عصبية مشتقة من خلايا جذعية من أشخاص يعانون من الاكتئاب المقاوم للعلاج (TRD) والاضطراب الاكتئابي الشديد (MDD)، مع الاستفادة من علامة اللدونة العصبية المملوكة لشركة للمقارنة بين الآثار الخلوية بين المركبات وربط النتائج بالأنماط السريرية.
تهدف التعاون إلى تضييق الفجوة بين النماذج قبل السريرية ونتائج المرضى وتوجيه أساليب دقيقة لتطوير الأدوية المهلوسة.
- None.
- None.
Insights
R&D partnership ties NeuroKaire's AI platform to Compass' psychedelic development capabilities; this could accelerate cellular‑level insights for depression treatments.
The collaboration pairs NeuroKaire and Compass Pathways to test how psychedelic compounds affect structure and connectivity in patient‑derived, stem cell‑derived neurons from individuals with treatment‑resistant depression (TRD) and major depressive disorder (MDD). The work will apply NeuroKaire's proprietary platform and AI image analysis to a proprietary neuroplasticity marker to compare cellular responses across compounds.
Key dependencies include successful generation of meaningful cellular readouts from the stem cell models and clear differentiation between compound effects using the neuroplasticity marker. Risks include technical reproducibility and whether cellular signals will translate to clinical efficacy; the announcement contains no clinical or financial milestones to verify near‑term commercial impact.
Watch for published assay validation, shared experimental endpoints, and any disclosed timelines or go‑forward studies; the press release date is
The study focuses on mechanistic, cell‑level interrogation of psychedelics using patient‑derived neurons and AI, offering a potential bridge from preclinical biology to therapeutic hypotheses.
The planned experiments will measure neuronal structure and connectivity in stem cell‑derived neurons from patients with TRD and MDD, using a proprietary neuroplasticity marker and AI‑driven image analysis to detect compound‑specific effects. This design targets mechanistic clarity rather than immediate clinical claims.
Primary scientific dependencies are the fidelity of patient‑derived neuron models to disease phenotypes and the sensitivity and specificity of the neuroplasticity marker; neither are quantified in the release. The work may inform candidate selection or biomarker hypotheses, but the announcement does not state validated endpoints, regulatory plans, or clinical translations.
Concrete items to monitor include assay validation results, any peer‑reviewed methods or data releases, and announced next steps from the collaboration; reference point is
Collaboration will leverage AI-powered neural analysis and Compass' expertise in psychedelic drug development to advance new therapies for mental health
This collaboration aims to deepen the mechanistic understanding of psychedelic compounds by testing the structure of, and connectivity between neurons (brain cells) using patient-derived neurons with known clinical phenotypes. The study will make use of stem cell derived-neurons from individuals with treatment-resistant depression (TRD) and major depressive disorder (MDD).
The planned study leverages NeuroKaire's proprietary platform, which applies cutting edge biology and AI-powered image analysis to see how various compounds affect aspects of communication between the neurons using a proprietary neuroplasticity marker. This provides a unique window into the cellular mechanisms of these potential treatments, and to the differences between them.
This collaboration brings NeuroKaire together with a true global innovator. Compass Pathways is at the forefront of mental health innovation, committed to rigorous science and accelerating patient access to new evidence-based treatments.
Dr. Daphna Laifenfeld, Co-founder and CSO of NeuroKaire, described Compass as a "true innovator" and expressed excitement about unlocking new insights that could support the development of more effective, personalized treatments.
Similarly, Dr. Michael Gold, Chief R&D Officer at Compass Pathways, noted that "it is imperative to advance our understanding of how this class of compounds work to better serve patients. NeuroKaire's innovative approach has the potential to bring much needed precision and clarity to psychedelic drug development."
This joint effort supports a major shift in psychiatry, integrating human biology and machine learning to close the gap between preclinical research and real-world patient outcomes. By exploring how these compounds work at a cellular level, this study has the potential to guide additional research with the goal of developing novel therapeutics.
About NeuroKaire
NeuroKaire develops personalized medicine solutions to optimize treatment for psychiatric and neurological diseases. By using a patient's biological data, including blood samples and genetic background, NeuroKaire's platform aims to identify the optimal drug therapy for individuals. This approach helps eliminate the trial-and-error process, leading to faster treatment and fewer side effects. The company also partners with pharmaceutical and biotech companies to integrate precision medicine into their drug development pipelines. For more information, visit www.neurokaire.com.
About Compass Pathways
Compass Pathways plc (Nasdaq: CMPS) is a leading biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. They are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of investigational COMP360 synthetic psilocybin treatment, potentially a first in class treatment.
Logo: https://mma.prnewswire.com/media/2581575/5078811/NeuroKaire_Logo.jpg
Contact:
David Pattison
david@neurokaire.com
+1-617-420-1836
View original content:https://www.prnewswire.com/news-releases/neurokaire-enters-into-rd-collaboration-with-compass-pathways-to-pioneer-precision-treatments-for-depression-302599816.html
SOURCE NeuroKaire
FAQ
What did NeuroKaire and Compass Pathways (CMPS) announce on October 30, 2025?
How will the NeuroKaire–Compass study use patient-derived neurons for CMPS research?
What technologies will NeuroKaire apply in the collaboration with CMPS?
Will the NeuroKaire and CMPS collaboration directly change Compass Pathways (CMPS) clinical trials?
What patient populations are included in the NeuroKaire and CMPS study?
How might the NeuroKaire collaboration affect CMPS drug development timelines?
